Effect of the phytotherapeutic agent Eviprostat® on 17β-estradiol-induced nonbacterial inflammation in the rat prostate

Prostate

Volumn 69, Issue 13, 2009, Pages 1404-1410

  Oka, Michiko ^a   Ueda, Makoto ^a   Oyama, Tatsuya ^a   Kyotani, Junko ^a   Tanaka, Mitsushi ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

Cytokines; Eviprostat ; Oxidative stress; Prostate inflammation; Rat nonbacterial prostatitis model

Indexed keywords

CERNITIN; ESTRADIOL; EVIPROSTAT; INTERLEUKIN 6; INTERLEUKIN 8; MALONALDEHYDE; POLYSORBATE 80; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CASTRATION; CHRONIC PROSTATITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; HISTOLOGY; LIPID PEROXIDATION; LOW DRUG DOSE; MALE; NONHUMAN; ORGAN WEIGHT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; SHAM PROCEDURE; THERAPY EFFECT; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; ESTRADIOL; ETHAMSYLATE; MALE; ORCHIECTOMY; ORGAN SIZE; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATITIS; RATS; RATS, WISTAR;

EID: 69449086417     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20985     Document Type: Article

References (26)

1. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol 1998;159:1224-1228.
2. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-237.
3. Vykhovanets EV, Resnick MI, MacLennan GT, Gupta S. Experimental rodent models of prostatitis: Limitations and potential. Prostate Cancer Prostatic Dis 2007;10:15-29. (Pubitemid 46358907)
4. Nadler RB, Koch AE, Calhoun EA, Campbell PL, Pruden DL, Bennett CL, Yarnold PR, Schaeffer AJ. IL-1β and TNF-α in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol 2000;164:214-218.
5. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L. Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007;51:524-533. (Pubitemid 44937795)
6. Pasqualotto FF, Sharma RK, Potts JM, Nelson DR, Thomas AJ, Agarwal A. Seminal oxidative stress in patients with chronic prostatitis. Urology 2000;55:881-885. (Pubitemid 30330792)
7. Sugaya K, Nishijima S, Tasaki S, Kadekawa K, Miyazato M, Ogawa Y. Mechanisms by which a phytotherapeutic drug influences bladder activity in rats. J Urol 2008;179:770-774.
8. Oka M, Tachibana M, Noda K, Inoue N, Tanaka M, Kuwabara K. Relevance of anti-reactive oxygen species activity to anti-inflammatory activity of components of eviprostat, a phytotherapeutic agent for benign prostatic hyperplasia. Phytomedicine 2007;14:465-472. (Pubitemid 47068955)
9. Oka M, Fukui T, Ueda M, Tagaya M, Oyama T, Tanaka M. Suppression of bladder oxidative stress and inflammation by a phytotherapeutic agent in a rat model of partial bladder outlet obstruction. J Urol 2009;182:382-390.
10. Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol 1988;140:1049-1053.
11. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001;87:797-805.
12. Robinette CL. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 1988;12:271-286.
13. Kamijo T, Sato S, Kitamura T. Effect of cernitin pollen-extract on experimental nonbacterial prostatitis in rats. Prostate 2001;49:122-131. (Pubitemid 32937808)
14. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992;66:96-107.
15. Buck AC, Rees RW, Ebeling L. Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol 1989;64:496-499. (Pubitemid 20018591)
16. Buck AC, Cox R, Rees RW, Ebeling L, John A. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernitin pollen extract. A double-blind, placebo-controlled study. Br J Urol 1990;66:398-404. (Pubitemid 20342715)
17. Shahed AR, Shoskes DA. Oxidative stress in prostatic fluid of patients with chronic pelvic pain syndrome: Correlation with gram positive bacterial growth and treatment response. J Androl 2000;21:669-675.
18. Sasaki Y, Fukui T, Kimura Y, Ogasawara T, Ukai Y. Eviprostat, a drug for benign prostatic hyperplasia, ameliorates the urodynamic disturbance in rats with cystitis and with chronic urethral obstruction. Jpn Pharmacol Ther 2000;28:463-471. (Pubitemid 30692134)
19. Kobayashi M, Nomura M, Nishii H, Matsumoto S, Fujimoto N, Matsumoto T. Effect of eviprostat on bladder overactivity in an experimental cystitis rat model. Int J Urol 2008;15:356-360.
20. Oka M, Noda K, Inoue N, Tanaka M. Anti-reactive oxygen species activity and anti-inflammatory activity of Eviprostat, a phytotherapeutic agent for benign prostatic hyperplasia. Relevance to the protective effect on the lower urinary tract dysfunction induced by ischemia/reperfusion injury. Nippon Hainyo Kino Gakkai Shi 2007;18:299-306 (in Japanese with English abstract).
21. Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 2000;44:19-25.
22. Taniguchi S, Taoka R, Inui M, Sugimoto M, Kakehi Y. Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate. Urology 2009;73:410-414.
23. Asakawa K, Nandachi N, Satoh S, Honma M, Namikata S, Ishii M, Yasumoto R, Nishisaka N, Masuda C, Kishimoto T. Effects of cernitin pollen-extract (Cernilton) on inflammatory cytokines in sex-hormone-induced nonbacterial prostatitis rats. Hinyokika Kiyo 2001;47:459-465 (in Japanese with English abstract).
24. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84:976-981.
25. Roehrborn CG. Definition of at-risk patients: Baseline variables. BJU Int 2006;97 (Suppl 2):7-11. (Pubitemid 43356988)
26. Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004;172:1784-1791. (Pubitemid 39363056)